Johnson & Johnson (JNJ) announced updated results from the investigational Phase 1b RedirecTT-1 study evaluating the bispecific antibody combination of TALVEY, and TECVAYLI, showing high response rates and durable responses, with a consistent safety profile to each monotherapy, in patients with relapsed or refractory multiple myeloma who were triple-class exposed, including those with extramedullary disease.
Jordan Schecter, Vice President, Disease Area Leader, Multiple Myeloma, Innovative Medicine at Johnson & Johnson, said: "We continue to research this innovative combination, as this study demonstrates both the efficacy and manageable safety profile of this combination, particularly in hard-to-treat patients such as those with EMD, as well as the combinability of TALVEY with other effective therapies."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.